SIONNA THERAPEUTICS, INC. Assets, Fair Value Disclosure
SIONNA THERAPEUTICS, INC. (SION) had Assets, Fair Value Disclosure of $267.75 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Assets, Fair Value Disclosure $267.75M.
- 2026-03-31: Assets, Fair Value Disclosure $289.43M.
- 2025-12-31: Assets, Fair Value Disclosure $309.80M.
- 2025-09-30: Assets, Fair Value Disclosure $324.50M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $267.75M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $289.43M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $309.80M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $324.50M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $336.77M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $354.19M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $167.54M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |